Page 16 - hypertension_newsletter6

REFLECTIONS
Hypertension
Hypertension Global Newsletter #6 2024

TREATMENT Hypertension

9. The pivotal role of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in hypertension
management and cardiovascular and renal protection: A critical appraisal and comparison of international
guidelines. Am J Cardiovasc Drugs. 2023 Nov;23(6):663-682.

10. Intensive blood pressure lowering improves left ventricular hypertrophy in older patients with hypertension: The
STEP Trial. Deng Y, et al. Hypertension. 2023 Sep;80(9):1834-1842.

11. Middle-aged and older patients with left ventricular hypertrophy: Higher mortality with drug treated systolic blood
pressure below 130 mm Hg. Heimark S, et al. Hypertension. 2023 Aug;80(8):1739-1748.

12. Evaluation of the stopping angiotensin converting enzyme inhibitor compared to angiotensin receptor blocker
(STOP ACEi trial) in advanced and progressive chronic kidney disease. Bhandari S, et al. Kidney Int. 2023 Sep
30:S0085-2538(23)00676-2.

13. β blockers switched to first-line therapy in hypertension. Messerli FH, et al. Lancet. 2023 Nov 11;402(10414):1802-
1804.
GUIDELINES/CONSENSUS STATEMENTS/POSITION PAPERS

14. Implementation strategies to improve blood pressure control in the United States: A scientific statement
From the American Heart Association and American Medical Association. Abdalla M, et al. Hypertension. 2023
Oct;80(10):e143-e157.

CONFERENCE CORNER

The ESC Congress, hosted in Amsterdam in Aug 25–28, 2023, is the annual meeting of the European Society of Cardiology. We
present below some abstracts of interest that may have an impact on clinical practice. Please click on the links to explore the
abstracts in more detail.

1. Associations of long-term visit-to-visit blood pressure variability with subclinical
kidney damage and albuminuria in adulthood: A 30-year prospective cohort study.
Wang Y, et al. Eur Heart J. 2023;44(Suppl 2) ehad655.2302.

2. Association of hydrochlorothiazide treatment compared to alternative diuretics with
overall and skin cancer risk: A propensity-matched cohort study. Goetzinger F, et al.
Eur Heart J. 2023;44(Suppl 2), ehad655.2311.

3. Systolic blood pressure visit-to-visit variability and outcomes in Asian patients
with established or multiple risk factors for atherosclerotic cardiovascular disease:
Results from the CORE-Thailand. Chichareon P, et al. Eur Heart J. 2023;44(Suppl 2),
ehad655.2326.

4. Ten year follow-up study regarding treatment compliance and cardiovascular events in young first diagnosed and
never treated hypertensives of a European Society of Hypertension Excellence Center. Triantafyllidi H, et al. Eur Heart
J. 2023;44(Suppl 2). ehad655.2315.

5. Comparing cardiovascular outcomes and costs of perindopril-, enalapril- or losartan-based antihypertensive
regimens in South Africa: Real-world medical claims database analysis. Snyman JR, et al. Eur Heart J. 2023;44(Suppl
2). ehad655.2320.

TABLE OF CONTENTS